Real-world glycemic outcomes of a tubeless automated insulin delivery system: a single-center observational study in Italy.
The objective of this study is to describe the short-term change observed in CGM-related measures and relevant clinical variables in individuals with type 1 diabetes transitioning to Omnipod 5 insulin treatment within a real-world setting.
The study involved adults with type 1 diabetes treated with Omnipod 5, whose data were collected over a 14-days observation period prior to (Time 0) and following the (Time 1) initiation of the patch pump use.
A total of 20 adults with well-controlled glycemia were included in the study. From baseline to follow-up, Time in Range (TIR) significantly increased from 57.3% to 67.3% (P<0.001). Concurrently, there were significant decreases in Time Above Range (TAR) Level 1 (mean difference, -4.7 ± 6.1%, P = 0.003) and Level 2 (-4.2 ± 6.1%, P = 0.018), as well as in Time Below Range (TBR) Level 1 (-1.0 ± 1.1%, P<001), TBR Level 2 (-0.4 ± 0.5%, P = 0.015), and Glycemia Risk Index (-13.8 ± 15.1 P<0.001). Importantly, no significant changes in insulin doses were observed during the study period.
Omnipod 5 initiation allowed participants to improve CGM-related metrics and the quality of glucose control in the short-term, without increasing the need for insulin.
The study involved adults with type 1 diabetes treated with Omnipod 5, whose data were collected over a 14-days observation period prior to (Time 0) and following the (Time 1) initiation of the patch pump use.
A total of 20 adults with well-controlled glycemia were included in the study. From baseline to follow-up, Time in Range (TIR) significantly increased from 57.3% to 67.3% (P<0.001). Concurrently, there were significant decreases in Time Above Range (TAR) Level 1 (mean difference, -4.7 ± 6.1%, P = 0.003) and Level 2 (-4.2 ± 6.1%, P = 0.018), as well as in Time Below Range (TBR) Level 1 (-1.0 ± 1.1%, P<001), TBR Level 2 (-0.4 ± 0.5%, P = 0.015), and Glycemia Risk Index (-13.8 ± 15.1 P<0.001). Importantly, no significant changes in insulin doses were observed during the study period.
Omnipod 5 initiation allowed participants to improve CGM-related metrics and the quality of glucose control in the short-term, without increasing the need for insulin.
Authors
Angelino Angelino, Maiorino Maiorino, Petrizzo Petrizzo, Di Martino Di Martino, Caruso Caruso, Carbone Carbone, Pontillo Pontillo, Maio Maio, Longo Longo, Scappaticcio Scappaticcio, Bellastella Bellastella, Esposito Esposito
View on Pubmed